Want to see AU:CMP full AI Analyst Report?
Top Page
Compumedics Limited
(Sydney:CMP)
Select Model
Select Model
Rating:61Neutral
Price Target:
AU$0.28
▼(-17.65% Downside)
Action:Reiterated
Date:08/26/26
The score is driven primarily by improving financial performance (strong 2026 cash flow rebound and steady revenue growth) and supportive technicals (trading above shorter-term averages with mildly positive momentum). These positives are offset by valuation risk, with an extremely high P/E that leaves little margin for execution missteps given still-thin net profitability.
Positive Factors
Steady revenue growth and resilient gross margins
Sustained revenue expansion indicates growing demand for the company’s sleep and neurodiagnostic systems. Resilient gross margins provide a durable foundation for scaling, although operating leverage must continue improving to convert growth into stronger earnings.
Negative Factors
Very thin net profitability
Near-break-even profitability leaves limited protection against higher manufacturing, support, or distribution costs. The low return on equity also shows that the growing revenue base and balance sheet are not yet producing consistently strong shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue growth and resilient gross margins
Sustained revenue expansion indicates growing demand for the company’s sleep and neurodiagnostic systems. Resilient gross margins provide a durable foundation for scaling, although operating leverage must continue improving to convert growth into stronger earnings.
Read all positive factors
Compumedics Limited (CMP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$49.94M
Dividend YieldN/A
Average Volume (3M)55.76K
Price to Earnings (P/E)227.3
Beta (1Y)0.74
Revenue Growth18.54%
EPS GrowthN/A
CountryAU
Employees175
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)<0.01
Shares Outstanding199,761,750
10 Day Avg. Volume142,556
30 Day Avg. Volume55,760
Financial Highlights & Ratios
PEG Ratio-2.23
Price to Book (P/B)2.40
Price to Sales (P/S)0.91
P/FCF Ratio8.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$75.60M
Compumedics Limited Business Overview & Revenue Model
Company Description
Compumedics Limited is a global medical technology enterprise engaged in the full lifecycle of designing, producing, marketing, and distributing advanced diagnostic medical devices. Its market reach extends across Australia, the Asia Pacific regio...
How the Company Makes Money
Compumedics makes money mainly by selling medical devices and related software systems used for sleep and neurodiagnostic testing. Its revenue model is largely product-based, supplemented by recurring and services-related income streams. Key reven...
Compumedics Limited Financial Statement Overview
Summary
Income Statement
61
Positive
Balance Sheet
64
Positive
Cash Flow
70
Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 60.25M | 51.04M | 49.72M | 42.41M | 37.76M |
| Gross Profit | 30.98M | 30.99M | 26.07M | 21.59M | 19.32M |
| EBITDA | 3.98M | 1.94M | 2.79M | -5.05M | 3.31M |
| Net Income | 214.00K | -1.27M | -338.00K | -6.12M | 1.36M |
Balance Sheet | |||||
| Total Assets | 56.63M | 54.39M | 40.36M | 41.18M | 41.71M |
| Cash, Cash Equivalents and Short-Term Investments | 6.15M | 2.69M | 1.89M | 3.80M | 7.29M |
| Total Debt | 14.11M | 13.88M | 8.58M | 9.47M | 6.55M |
| Total Liabilities | 33.92M | 32.57M | 22.15M | 22.89M | 18.12M |
| Stockholders Equity | 22.71M | 21.82M | 18.21M | 18.29M | 23.59M |
Cash Flow | |||||
| Free Cash Flow | 6.42M | 467.00K | -986.00K | -4.36M | 302.00K |
| Operating Cash Flow | 6.61M | 681.00K | 2.00M | 49.00K | 3.29M |
| Investing Cash Flow | -3.90M | -7.37M | -2.99M | -4.41M | -2.98M |
| Financing Cash Flow | 4.26M | 6.10M | -1.49M | -1.00M | 1.61M |
Compumedics Limited Technical Analysis
Negative
0.34
Price Trends
0.24
Positive
0.26
Negative
0.30
Negative
Market Momentum
<0.01
Negative
52.74
Neutral
37.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CMP, the sentiment is Negative. The current price of 0.34 is above the 20-day moving average (MA) of 0.24, above the 50-day MA of 0.24, and above the 200-day MA of 0.30, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.74 is Neutral, neither overbought nor oversold. The STOCH value of 37.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CMP.
Compumedics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | AU$45.65B | 21.87 | 23.88% | 1.02% | 4.74% | 4.44% | |
61 Neutral | AU$49.94M | 227.27 | 0.93% | ― | 18.54% | ― | |
54 Neutral | AU$75.82M | -28.51 | -5.44% | ― | 2.73% | 25.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$174.76M | -20.59 | -46.84% | ― | ― | 20.40% | |
46 Neutral | AU$2.17B | -9.13 | -288.42% | ― | 20.64% | -457.40% | |
45 Neutral | AU$42.87M | -12.12 | -198.77% | ― | -52.35% | 40.38% |
* Healthcare Sector Average
AU:CMP
Compumedics Limited
0.25
-0.05
-16.67%
AU:SOM
Somnomed Limited
0.35
-0.41
-54.00%
AU:HMD
HeraMED Ltd.
0.04
<0.01
5.56%
AU:EMV
EMvision Medical Devices Ltd.
1.88
-0.33
-14.93%
AU:4DX
4DMedical Ltd
3.52
1.84
109.52%
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
31.39
-10.37
-24.83%
Compumedics Limited Corporate Events
Compumedics posts record FY26 revenue and sharp EBITDA growth on SaaS and MEG gains
Aug 25, 2026
Compumedics reported record FY26 revenue of $60.3 million, up 18.5% year on year, with EBITDA jumping 72.1% to $5.4 million, a return to NPAT profitability and operating cash inflow of $6.6 million that materially strengthened its balance sheet. T...
Compumedics Returns to Profit on Record Revenue and MEG-Led Growth
Aug 25, 2026
Compumedics reported a strong financial rebound for the year to 30 June 2026, delivering record shipped and invoiced revenue as well as a return to profitability. The group’s earnings before interest, tax, depreciation and amortisation rose ...
Compumedics posts record FY26 revenue as SaaS platforms drive growth
Jul 6, 2026
Compumedics expects to deliver record FY26 shipped and invoiced revenue of about $60.3 million, up roughly 18% year-on-year, underpinned by solid demand for sleep and neurology diagnostics and its MEG and connected platform businesses. The company...
Compumedics Taps Veteran Medtech Leader to Drive U.S. Growth
Jun 9, 2026
Compumedics Limited, a global provider of sleep diagnostics, neurodiagnostic systems and ultrasonic blood flow monitoring technology, has expanded from its Australian base through its Neuroscan and DWL subsidiaries into key international markets. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.